UPB

Upstream Bio, Inc.
CAPPED RATING

Upstream Bio, Inc. (UPB) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Momentum (D-). The rating has held at C- for 11 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
B
Factor Score 3.2 / 5.0
Growth
D
Factor Score 1.2 / 5.0
Profitability
C-
Factor Score 1.9 / 5.0
Momentum
D-
Factor Score 0.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.1
EV / EBITDA 0.3
Rev Growth YoY -42.2%
Gross Margin N/M
Price Return 3M -61.1%
Price Return 12M -88.3%
Catalyst Signal 0.00
Market Cap $152.4M
TTM Revenue $2.9M
Price / Sales 53.1
ROE -53.5%

Historical Factor Score Progression

Held C- for 11 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B (3.2) D (1.2) C- (1.9) D- (0.7) C+ (2.6) C- (1.9)
2026-11-08 B (3.3) D (1.3) C- (2.0) D- (0.9) C+ (2.6) C- (2.0)
2026-11-01 B- (3.1) D (1.3) C- (2.1) D- (1.1) C+ (2.7) C- (2.1)
2026-10-25 B (3.2) D (1.3) C- (2.1) D- (0.9) C+ (2.6) C- (2.0)
2026-10-18 B (3.2) D (1.3) C- (2.1) D- (0.8) C+ (2.6) C- (2.0)
Page 1 of 3